Atlas Trials

A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients

Clinical trial NCT04200040 · UNKNOWN

Trial details

NCT number
NCT04200040
Sponsor
OrienGene Biotechnology Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Melanoma (Skin)
Start date
2017-08-27
Primary completion
2022-12-27
Enrollment
165

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.